Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and wellness in breast aesthetics and reconstruction, will announce its Q2 2024 financial results on August 6, 2024, after market close. The company will host a conference call at 4:30 pm ET to discuss the results. Investors can dial (800) 715-9871 (U.S. and Canada) or (646) 307-1963 (International) using conference ID 7160745 to participate.
Establishment Labs has delivered over 3 million Motiva® devices to surgeons since 2010, setting new standards for safety and patient satisfaction in over 85 countries. The company's portfolio includes the Motiva Flora® tissue expander and Mia Femtech™ for minimally invasive breast harmony. With 200+ patent applications and 50+ scientific studies, Establishment Labs manufactures in Costa Rica under strict regulatory standards.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), una società globale di tecnologia medica focalizzata sulla salute e il benessere delle donne nell'estetica e nella ricostruzione mammaria, annuncerà i risultati finanziari del secondo trimestre 2024 il 6 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una chiamata conferenza alle 16:30 ET per discutere i risultati. Gli investitori possono collegarsi componendo il numero (800) 715-9871 (Stati Uniti e Canada) o (646) 307-1963 (internazionale) utilizzando l'ID della conferenza 7160745 per partecipare.
Establishment Labs ha consegnato oltre 3 milioni di dispositivi Motiva® ai chirurghi dal 2010, stabilendo nuovi standard per la sicurezza e la soddisfazione del paziente in oltre 85 paesi. Il portafoglio dell'azienda include l'espansore tissutale Motiva Flora® e Mia Femtech™ per un'armonia mammaria minimamente invasiva. Con oltre 200 domande di brevetto e più di 50 studi scientifici, Establishment Labs produce in Costa Rica secondo rigorosi standard normativi.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), una empresa global de tecnología médica centrada en la salud y el bienestar de las mujeres en la estética y reconstrucción mamaria, anunciará sus resultados financieros del segundo trimestre de 2024 el 6 de agosto de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia a las 4:30 pm ET para discutir los resultados. Los inversores pueden marcar (800) 715-9871 (EE. UU. y Canadá) o (646) 307-1963 (internacional) utilizando el ID de conferencia 7160745 para participar.
Establishment Labs ha entregado más de 3 millones de dispositivos Motiva® a cirujanos desde 2010, estableciendo nuevos estándares de seguridad y satisfacción del paciente en más de 85 países. El portafolio de la empresa incluye el expansor de tejido Motiva Flora® y Mia Femtech™ para una armonía mamaria mínimamente invasiva. Con más de 200 solicitudes de patente y más de 50 estudios científicos, Establishment Labs fabrica en Costa Rica bajo estrictos estándares regulatorios.
Establishment Labs Holdings Inc. (NASDAQ: ESTA)는 여성 건강 및 웰니스, 특히 유방 미용 및 재건에 중점을 둔 글로벌 의료 기술 회사로서, 2024년 2분기 재무 결과를 2024년 8월 6일 시장 종료 후 발표할 예정입니다. 회사는 재무 결과를 논의하기 위해 동부 표준시 기준으로 오후 4시 30분에 컨퍼런스 콜을 개최합니다. 투자자들은 (800) 715-9871 (미국 및 캐나다) 또는 (646) 307-1963 (국제)로 전화하여 컨퍼런스 ID 7160745를 입력하여 참여할 수 있습니다.
Establishment Labs는 2010년부터 외과 의사에게 300만 개 이상의 Motiva® 장치를 제공해 왔으며, 85개국 이상에서 안전성과 환자 만족도를 위한 새로운 기준을 설정했습니다. 이 회사의 포트폴리오에는 Motiva Flora® 조직 확장기와 미세 침습적 유방 조화를 위한 Mia Femtech™가 포함되어 있습니다. 200건 이상의 특허 출원과 50건 이상의 과학 연구를 보유한 Establishment Labs는 Costa Rica에서 엄격한 규제 기준에 따라 제조합니다.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), une entreprise mondiale de technologie médicale axée sur la santé et le bien-être des femmes dans l'esthétique et la reconstruction mammaire, annoncera ses résultats financiers pour le deuxième trimestre 2024 le 6 août 2024, après la fermeture du marché. La société organisera une conférence téléphonique à 16h30 ET pour discuter des résultats. Les investisseurs peuvent composer le (800) 715-9871 (États-Unis et Canada) ou le (646) 307-1963 (international) en utilisant l'ID de conférence 7160745 pour participer.
Establishment Labs a livré plus de 3 millions de dispositifs Motiva® aux chirurgiens depuis 2010, établissant de nouvelles normes en matière de sécurité et de satisfaction des patients dans plus de 85 pays. Le portefeuille de l'entreprise comprend le dilatateur tissulaire Motiva Flora® et Mia Femtech™ pour une harmonie mammaire peu invasive. Avec plus de 200 demandes de brevet et plus de 50 études scientifiques, Establishment Labs fabrique au Costa Rica selon des normes réglementaires strictes.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), ein globales Medizintechnikunternehmen, das sich auf die Gesundheit und das Wohlbefinden von Frauen in der Brustästhetik und -rekonstruktion konzentriert, wird am 6. August 2024 nach Börsenschluss die Finanzzahlen für das zweite Quartal 2024 bekannt geben. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können unter (800) 715-9871 (USA und Kanada) oder (646) 307-1963 (international) anrufen, um mit der Konferenz-ID 7160745 teilzunehmen.
Establishment Labs hat seit 2010 über 3 Millionen Motiva®-Geräte an Chirurgen ausgeliefert und neue Standards für Sicherheit und Patientenzufriedenheit in über 85 Ländern gesetzt. Das Produktportfolio des Unternehmens umfasst den Motiva Flora® Gewebeexpander und Mia Femtech™ für minimalinvasive Brustharmonie. Mit über 200 Patentanmeldungen und mehr als 50 wissenschaftlichen Studien produziert Establishment Labs in Costa Rica unter strengen regulatorischen Standards.
- Delivered over 3 million Motiva® devices since 2010
- Products available in more than 85 countries
- Portfolio includes innovative products like Motiva Flora® and Mia Femtech™
- Over 200 patent applications in 25 separate patent families
- More than 50 scientific studies published in peer-reviewed journals
- None.
To participate in the conference call, dial (800) 715-9871 (
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724558436/en/
Investor/Media Contact:
Raj Denhoy
415 828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
When will Establishment Labs (ESTA) release Q2 2024 financial results?
How can investors participate in Establishment Labs' (ESTA) Q2 2024 earnings call?
How many Motiva® devices has Establishment Labs (ESTA) delivered since 2010?
In how many countries are Establishment Labs' (ESTA) products available?
